Flynn Joseph T
Division of Paediatric Nephrology, Montefiore Medical Center, 111 East 210th Street, Bronx, NY 10467, USA.
Expert Opin Drug Saf. 2003 Mar;2(2):133-9. doi: 10.1517/14740338.2.2.133.
Short-acting nifedipine has been abandoned as a treatment for severe hypertension in adults as a result of significant adverse effects. Despite this, it remains a popular choice for the treatment of severe hypertension in children. However, recent publications describing adverse effects of short-acting nifedipine in children similar to those reported in adults, have prompted some experts to question the continued use of this agent in children. In this review, available data on the pharmacology, clinical efficacy and safety of short-acting nifedipine are reviewed, and the advisability of using short-acting nifedipine is reassessed. Although low (< 0.25 mg/kg) doses of short-acting nifedipine may be safe in some hypertensive children, alternative agents that produce more controlled reductions in blood pressure, and that are easier to accurately dose and administer, should probably be chosen for the majority of children with severe hypertension.
由于存在显著的不良反应，短效硝苯地平已不再用于治疗成人重度高血压。尽管如此，它仍是治疗儿童重度高血压的常用选择。然而，最近有文献报道短效硝苯地平在儿童中产生的不良反应与成人相似，这促使一些专家质疑该药在儿童中的持续使用。在本综述中，我们回顾了关于短效硝苯地平的药理学、临床疗效和安全性的现有数据，并重新评估了使用短效硝苯地平的合理性。虽然低剂量（<0.25mg/kg）的短效硝苯地平在一些高血压儿童中可能是安全的，但对于大多数重度高血压儿童，可能应选择能更平稳降低血压、更容易精确给药的替代药物。
